Analyst Ratings for [IRON] Disc Medicine, Inc.

7/21/25	Initiated	Buy	X
IRON Disc Medicine Truist
$86
7/3/25	Resumed	Overweight	X
IRON Disc Medicine Morgan Stanley
$85
6/11/25	Resumed	Strong Buy	X
IRON Disc Medicine Raymond James
$89
2/27/25	Initiated	Buy	X
IRON Disc Medicine TD Cowen
11/5/24	Upgrades	Eq-Weight Overweight	X
IRON Disc Medicine Morgan Stanley
$85
11/4/24	Upgrades	Outperform Strong Buy	X
IRON Disc Medicine Raymond James
$66 $110
10/23/24	Initiated	Buy	X
IRON Disc Medicine Jefferies
$89
10/16/24	Initiated	Sector Outperform	X
IRON Disc Medicine Scotiabank
8/22/24	Initiated	Overweight	X
IRON Disc Medicine Wells Fargo
$75
4/1/24	Downgrades	Strong Buy Outperform	X
IRON Disc Medicine Raymond James
$40
12/19/23	Downgrades	Overweight Eq-Weight	X
IRON Disc Medicine Morgan Stanley
$56 $65
6/9/23	Upgrades	Outperform Strong Buy	X
IRON Disc Medicine Raymond James
$50 $75
6/7/23	Initiated	Buy	X
IRON Disc Medicine H.C. Wainwright
$55
5/17/23	Initiated	Outperform	X
IRON Disc Medicine Raymond James
$50
4/28/23	Initiated	Overweight	X
IRON Disc Medicine Cantor Fitzgerald
$45
4/21/23	Initiated	Buy	X
IRON Disc Medicine Stifel
$37
4/20/23	Initiated	Overweight	X
IRON Disc Medicine Morgan Stanley
$37
3/23/23	Initiated	Outperform	X
IRON Disc Medicine BMO Capital Markets
$40
2/28/23	Initiated	Outperform	X
IRON Disc Medicine SVB Securities
$36

IRON Disc Medicine, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.